I agree that this site is using cookies. You can find further informations here.
X
Gopalakrishnan, Sathej
31  results:
Search for persons X
?
1

Asia‐Inclusive Global Development of Enpatoran: Results of ..:

Klopp‐Schulze, Lena ; Gopalakrishnan, Sathej ; Yalkinoglu, Özkan...
Clinical Pharmacology & Therapeutics.  115 (2024)  6 - p. 1346-1357 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Evobrutinib pathway to its major metabolite M463-2 and insi..:

Scheible, Holger ; Schieferstein, Hanno ; Schmidt, Ralf...
Xenobiotica.  53 (2023)  8-9 - p. 547-558 , 2023
Link: https://doi.org/10.1080/..
 
?
3

Venetoclax in biomarker‐selected multiple myeloma patients:..:

Badawi, Mohamed ; Coppola, Sheryl ; Eckert, Doerthe...
Hematological Oncology.  42 (2023)  1 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
4

Relationship Between Venetoclax Exposure and Undetectable M..:

Gopalakrishnan, Sathej ; Menon, Rajeev ; Suleiman, Ahmed A....
HemaSphere.  7 (2023)  12 - p. e983 , 2023
Link: https://doi.org/10.1097/..
 
?
5

Venetoclax exposure‐efficacy and exposure‐safety relationsh..:

Brackman, Deanna ; Eckert, Doerthe ; Menon, Rajeev...
Hematological Oncology.  40 (2022)  2 - p. 269-279 , 2022
Link: https://doi.org/10.1002/..
 
?
6

Alternatives to rifampicin: A review and perspectives on th..:

Bolleddula, Jayaprakasam ; Gopalakrishnan, Sathej ; Hu, Ping..
Clinical and Translational Science.  15 (2022)  9 - p. 2075-2095 , 2022
Link: https://doi.org/10.1111/..
 
?
7

Upadacitinib pharmacokinetics and exposure‐response analyse..:

Muensterman, Elena ; Engelhardt, Benjamin ; Gopalakrishnan, Sathej..
Clinical and Translational Science.  15 (2021)  1 - p. 267-278 , 2021
Link: https://doi.org/10.1111/..
 
?
8

Integrated Mechanistic Model of Minimal Residual Disease Ki..:

Gopalakrishnan, Sathej ; Wierda, William ; Chyla, Brenda...
Clinical Pharmacology & Therapeutics.  109 (2020)  2 - p. 424-432 , 2020
Link: https://doi.org/10.1002/..
 
?
9

Exposure‐Response Analyses for Upadacitinib Efficacy in Sub..:

Mohamed, Mohamed‐Eslam F. ; Gopalakrishnan, Sathej ; Teixeira, Henrique D..
The Journal of Clinical Pharmacology.  61 (2020)  5 - p. 628-635 , 2020
Link: https://doi.org/10.1002/..
 
?
10

MDS-090: Semi-Mechanistic Model to Aid Clinical Understandi..:

Thakre, Neha ; Maier, Corinna ; Zha, Jiuhong...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S312-S313 , 2020
Link: https://doi.org/10.1016/..
 
?
11

MDS-141: The Prognostic Impact of Cytogenetic Scores in Pat..:

Garcia, Jacqueline S ; Wei, Andrew H ; Borate, Uma...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S315-S316 , 2020
Link: https://doi.org/10.1016/..
 
?
12

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An..:

Dave, Nimita ; Gopalakrishnan, Sathej ; Mensing, Sven.
Clinical and Translational Science.  12 (2019)  6 - p. 625-632 , 2019
Link: https://doi.org/10.1111/..
 
?
13

Optimizing venetoclax dose in combination with low intensiv..:

Agarwal, Suresh ; Gopalakrishnan, Sathej ; Mensing, Sven...
Hematological Oncology.  37 (2019)  4 - p. 464-473 , 2019
Link: https://doi.org/10.1002/..
 
?
14

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Da..:

Gopalakrishnan, Sathej ; Mensing, Sven ; Menon, Rajeev M..
Clinical Pharmacokinetics.  57 (2018)  11 - p. 1407-1419 , 2018
Link: https://doi.org/10.1007/..
 
?
15

Exposure–Response Relationship for Ombitasvir and Paritapre..:

Gopalakrishnan, Sathej ; Khatri, Amit ; Mensing, Sven...
Advances in Therapy.  33 (2016)  4 - p. 670-683 , 2016
Link: https://doi.org/10.1007/..
 
1-15